Thus, the objective of this in vitro and in vivo study was to analyze the anti-tumor mechanism of tirabrutinib, a highly selective BTK inhibitor in ABC-DLBCL, using phosphoproteomic and transcriptomic techniques. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.